Skip to main content
Clinical Trials/JPRN-jRCTb030200391
JPRN-jRCTb030200391
Recruiting
Phase 3

The Efficacy of Platelet-Rich-Plasma for prevention of the knee joint cartilage degeneration after anterior cruciate ligament reconstruction: a single-blind randomized trial - The Efficacy of Platelet-Rich-Plasma for prevention of the knee joint cartilage degeneration after anterior cruciate ligament reconstruction

Yoshitomo Saita0 sites80 target enrollmentMarch 2, 2021

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Patients after anterior cruciate ligament reconstruction
Sponsor
Yoshitomo Saita
Enrollment
80
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 2, 2021
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Yoshitomo Saita

Eligibility Criteria

Inclusion Criteria

  • 1 At the time of obtaining consent, the age is between 20 and 50
  • 2 Male and female
  • 3 Kellgren\-Lawrence classification 2 or less
  • 4 Single bundle reconstruction surgery using semitendinosus tendon as reconstruction ligament
  • 5 First injury
  • 6 BMI is less than 35
  • 7 Those who have received a sufficient explanation, fully understood, and obtained free written consent.
  • 8 In addition, those who the doctor deems appropriate

Exclusion Criteria

  • 1 Ligament compound injury (posterior cruciate ligament, lateral support mechanism)
  • 2 Merge of medial collateral ligament injuries requiring repair
  • 3 Femoro\-Tibial Angle: FTA left and right difference is 10 degrees or more
  • 4 Whole body motor disease
  • 5 Patients with malignant neoplasms currently being treated
  • 6 Patients with active infectious disease (including HBV, HCV, HTLV\-1, HIV, syphilis)
  • 7 Rheumatoid arthritis
  • 8 Blood disease
  • 9 Mental illness
  • 10 pregnant

Outcomes

Primary Outcomes

Not specified

Similar Trials